clarivate analytics is the global leader in providing trusted insights and analytics to accelerate the pace of innovation. we offer some of the most trusted brands across the innovation lifecycle, including web of science™, cortellis™, derwent™, compumark™, markmonitor® and techstreet™. organizations and researchers rely on the curated knowledge bases from clarivate for information about scientific and academic research, patent analytics, pharmaceutical and biotech intelligence and ip management. an independent company with over 4,000 employees and operations in more than 100 countries, clarivate is on a bold entrepreneurial mission to help radically reduce the time from new ideas to life-changing innovations. for more information, please visit clarivate.com.
Company profile
Ticker
CLVT, CLVT-PA
Exchange
Website
CEO
Jonathan Gear
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Clarivate Analytics PLC
SEC CIK
Corporate docs
Subsidiaries
Camelot UK Bidco Ltd • Clarivate Analytics (Belgium) NV • Clarivate Analytics (Compumark) Inc • Clarivate Analytics (Japan) Co., Ltd • Clarivate Analytics (UK) Ltd • Clarivate Analytics (US) LLC • Clarivate IP (US) Holdings Corporation • CPA Global (Landon IP) Inc • CPA Global Limited • CPA Global Support Services LLC ...
CLVT stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
25 Mar 24
DEFA14A
Additional proxy soliciting materials
25 Mar 24
DEF 14A
Definitive proxy
25 Mar 24
S-8
Registration of securities for employees
12 Mar 24
8-K
Entry into a Material Definitive Agreement
4 Mar 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Clarivate Reports Fourth Quarter and Full Year 2023 Results
27 Feb 24
8-K
Clarivate Completes Refinancing of Term Loan and Revolver Extension
1 Feb 24
8-K
Clarivate Announces Commencement of Term Loan Refinancing Transaction
22 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
Transcripts
CLVT
Earnings call transcript
2023 Q4
27 Feb 24
CLVT
Earnings call transcript
2023 Q3
7 Nov 23
CLVT
Earnings call transcript
2023 Q2
3 Aug 23
CLVT
Earnings call transcript
2023 Q1
9 May 23
CLVT
Earnings call transcript
2022 Q4
1 Mar 23
CLVT
Earnings call transcript
2022 Q3
13 Nov 22
CLVT
Earnings call transcript
2022 Q2
13 Aug 22
CLVT
Earnings call transcript
2022 Q1
9 May 22
CLVT
Earnings call transcript
2021 Q4
10 Mar 22
CLVT
Earnings call transcript
2021 Q3
28 Oct 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 407.20 mm | 407.20 mm | 407.20 mm | 407.20 mm | 407.20 mm | 407.20 mm |
Cash burn (monthly) | 11.97 mm | 3.95 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 82.28 mm | 27.16 mm | n/a | n/a | n/a | n/a |
Cash remaining | 324.92 mm | 380.04 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 27.2 | 96.2 | n/a | n/a | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 243 |
Opened positions | 32 |
Closed positions | 63 |
Increased positions | 95 |
Reduced positions | 74 |
13F shares | Current |
---|---|
Total value | 3.70 tn |
Total shares | 890.58 mm |
Total puts | 66.70 k |
Total calls | 1.60 mm |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Farallon Capital Partners | 147.97 mm | $0.00 |
Leonard Green & Partners | 116.67 mm | $782.83 bn |
Green Equity Investors VII | 116.67 mm | $3.03 bn |
ONEX Onex | 41.92 mm | $985.89 mm |
Impactive Capital | 33.11 mm | $222.16 bn |
EXXRF Exor | 32.47 mm | $217.89 bn |
Generation Investment Management | 29.72 mm | $199.44 bn |
Elgin Investment | 27.77 mm | $0.00 |
BLK Blackrock | 25.70 mm | $172.46 bn |
Partners Group Holding | 25.58 mm | $171.66 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 24 | Andrew Miles Snyder | Ordinary Shares | Payment of exercise | Dispose F | No | No | 7.43 | 1,380 | 10.25 k | 65,016 |
31 Mar 24 | Andrew Miles Snyder | Ordinary Shares | Grant | Acquire A | No | No | 7.43 | 6,897 | 51.24 k | 66,396 |
31 Mar 24 | Jane L Okun Bomba | Ordinary Shares | Payment of exercise | Dispose F | No | No | 7.43 | 216 | 1.60 k | 126,587 |
31 Mar 24 | Jane L Okun Bomba | Ordinary Shares | Grant | Acquire A | No | No | 7.43 | 3,869 | 28.75 k | 126,803 |
31 Mar 24 | Roedel Richard | Ordinary Shares | Payment of exercise | Dispose F | No | No | 7.43 | 205 | 1.52 k | 70,510 |
31 Mar 24 | Roedel Richard | Ordinary Shares | Grant | Acquire A | No | No | 7.43 | 4,542 | 33.75 k | 70,715 |
15 Mar 24 | Julie M Wilson | Ordinary Shares | Grant | Acquire A | No | No | 0 | 169,971 | 0.00 | 363,653 |
News
Clarivate joins United Nations Sustainable Development Goals (UN SDGs) Publishers Compact
24 Apr 24
Exor Amplifies Stake In Clarivate, Proposes New Board Member
4 Mar 24
Morgan Stanley Maintains Equal-Weight on Clarivate, Lowers Price Target to $8
28 Feb 24
The Analyst Landscape: 5 Takes On Clarivate
28 Feb 24
Barclays Maintains Underweight on Clarivate, Lowers Price Target to $6
28 Feb 24
Press releases
Clarivate joins United Nations SDG Publishers Compact
24 Apr 24
Clarivate Launches LatAm Market Tracking Solution in Partnership with Global Healthcare Intelligence Enabling Real-Time Tracking of Medical Device Markets
17 Apr 24
Clarivate Acquires AI Start Up to Accelerate Strategy and Business Development Success for Life Sciences & Healthcare Clients
21 Mar 24
New Webinar: Clarivate in the Age of AI - Driving Innovation in Intellectual Property Management and Decision Making
20 Mar 24
New Webinar: Clarivate in the Age of AI - Empowering Our Life Sciences & Healthcare Customers to Create a Healthier Tomorrow
13 Mar 24